ARCA biopharma boosts CEO and CFO retention bonuses to $200K each

Oruka Therapeutics, Inc.

Board approved 33.33% increase in retention bonuses for Thomas A. Keuer and C. Jeffrey Dekker to $200,000 each.
Remaining $165,000 per executive payable on a corporate transaction or clinical development decision approval.
Amendments effective April 22, 2024; original retention letter terms otherwise unchanged.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.